Evidence map›Paper›PMID 31171038›Full record

ArticleArthritis research & therapy2019

Outcome of patients with early arthritis without rheumatoid factor and ACPA and predictors of rheumatoid arthritis in the ESPOIR cohort.

Gaël Mouterde, Nathalie Rincheval, Cédric Lukas, Claire Daien, Alain Saraux, Philippe Dieudé, Jacques Morel, Bernard Combe

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in Arthritis research & therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 31 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Gaël MouterdeRheumatology Department, CHU Montpellier, Univ Montpellier, Montpellier, France. g-mouterde@chu-montpellier.fr.ORCID 0000-0002-0651-5035
Nathalie RinchevalEA 2415, Montpellier, France.
Cédric LukasRheumatology Department, CHU Montpellier, Univ Montpellier, Montpellier, France.
Claire DaienRheumatology Department, CHU Montpellier, Univ Montpellier, Montpellier, France.
Alain SarauxRheumatology department, CHU de la Cavale Blanche & EA 2216, Brest, France.
Philippe DieudéRheumatology Department & INSERM U699, APHP, Bichat Hospital, Paris, France.
Jacques MorelRheumatology Department, CHU Montpellier, Univ Montpellier, Montpellier, France.
Bernard CombeRheumatology Department, CHU Montpellier, Univ Montpellier, Montpellier, France.
Université de Montpellier · FRCentre Hospitalier Régional Universitaire de Brest · FRNeuropsychiatrie : Recherche Epidemiologique et Clinique · FRUniversité Claude Bernard Lyon 1 · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo describe the disease course of patients with early arthritis without rheumatoid factor (RF) and anti-citrullinated protein auto-antibodies (ACPA) in an inception cohort. To determine baseline predictors of fulfilling 2010 ACR/EULAR criteria for rheumatoid arthritis (RA) for these patients within 3 years.

methodPatients included in the multicenter ESPOIR cohort were compared at baseline and 3 years by whether they were negative for RF and ACPA ("seronegative") or positive for RF and/or ACPA ("seropositive"). Univariate analysis was used to determine the association between baseline variables in seronegative patients and RA classification. Stepwise multiple logistic regression was used to identify predictors of RA classification within 3 years, estimating odds ratios (ORs).

resultsAmong 354 seronegative patients, 224/340 with available data (65.9%) fulfilled RA classification at baseline and 189/233 (81.1%) at 3 years. As compared with seropositive patients, seronegative patients had lower DAS28 (p = 0.002) and lower modified total Sharp score (mTSS; p = 0.026) at baseline; DAS28 remission was similar (p = 0.634), but radiographic progression rate was lower in seronegative patients (p <  0.001) at 3 years. In seronegative patients, factors predicting RA classification within 3 years were additive (OR = 3.61), bilateral (OR = 2.59) and hand, wrist or forefeet involvement (OR = 3.87); presence of a trigger event (OR = 3.57); pain at rest (OR = 2.76); morning stiffness (OR = 2.62); number of tender joints (OR = 23.73); and mTSS (OR = 2.56).

conclusion"Seronegative" patients have less active disease at baseline and less radiographic progression during follow-up than "seropositive" patients. With inflammatory pain, symmetric involvement of numerous small joints and erosive disease, a classification of RA is likely.

Indexed as

Antirheumatic AgentsArthritis, RheumatoidAutoantibodiesBiomarkersDisease ProgressionFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisRetrospective StudiesRheumatoid FactorSeverity of Illness IndexAntirheumatic AgentsAutoantibodiesBiomarkersRheumatoid FactorAnti-citrullinated protein antibodies (ACPA)ArthritisEarly arthritisESPOIR cohortRheumatoid arthritisRheumatoid factorSeronegative arthritis

Identifiers

PMID31171038
PMCPMC6555707
OpenAlexW2948062565

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.